Diasorin SpAWBO:DIAS +2.47%74 PS Ratio is 3.18 as of Jul. 02, 2026, which is 46% below its 10-year median of 5.92. GuruFocus rates WBO:DIAS with a GF Score™ of 74/100 and a GF Value™ of €90.06 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 200 Medical Diagnostics & Research companies, Diasorin SpA ranks worse than 55% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Diasorin SpA's share price is €69.68.
Diasorin SpA's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €21.90. Hence, Diasorin SpA's PS Ratio for today is 3.18.
The historical rank and industry rank for Diasorin SpA's PS Ratio or its related term are showing as below:
WBO:DIAS'
s PS Ratio Range Over the Past 10 Years
Min: 2.64 Med: 5.92 Max: 15.64
Current: 3.19
During the past 13 years, Diasorin SpA's highest PS Ratio was 15.64. The lowest was 2.64. And the median was 5.92.
WBO:DIAS's PS Ratio is ranked worse than 55% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.805
vs WBO:DIAS: 3.19
Diasorin SpA revenue per share has been in decline over the past 3 years.
During the past 3 years, the average Revenue per Share Growth Rate was -3.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 3.60% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 10.20% per year.
During the past 13 years, Diasorin SpA's highest 3-Year average Revenue per Share Growth Rate was 25.80% per year. The lowest was -3.30% per year. And the median was 9.95% per year.
Back to Basics: PS Ratio
Diasorin SpA (WBO:DIAS) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Diasorin SpA PS Ratio Related Terms
Diasorin SpA PS Ratio Historical Data
* Premium members only.
The historical data trend for Diasorin SpA's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Diasorin SpA's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diasorin SpA PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's PS Ratio distribution charts can be found below:
* The bar in red indicates where Diasorin SpA's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Diasorin SpA's PS Ratio for today is calculated as
Diasorin SpA's Share Price of today is €69.68. Diasorin SpA's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €21.90.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Diasorin SpA (WBO:DIAS) has a PS Ratio of 3.18 as of Jul. 02, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Diasorin SpA and its competitors. This is 46% below median its historical median of 5.92. Over the past decade, Diasorin SpA's PS Ratio has ranged from 2.64 to 15.64. According to the industry distribution chart, Diasorin SpA ranks #110 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 55%.
Is Diasorin SpA's PS Ratio too high?
Diasorin SpA's current PS Ratio of 3.18 is 46% below median its 10-year median of 5.92. Over the past 10 years, this metric has ranged from a low of 2.64 to a high of 15.64. The Medical Diagnostics & Research industry median PS Ratio is 2.81. Diasorin SpA's value of 3.18 is 13.4% above this industry median. Based on the distribution chart, Diasorin SpA ranks #110 out of 200 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Diasorin SpA has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diasorin SpA ranks #110 out of 200 companies for PS Ratio. This places Diasorin SpA in the lower half of its industry. The industry median PS Ratio is 2.81. Diasorin SpA's value of 3.18 is 13.4% above this benchmark. Historically, Diasorin SpA's own PS Ratio has ranged from 2.64 to 15.64 over the past decade. While the company's 10-year median is 5.92 vs. the industry median of 2.81, Diasorin SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.81, based on 200 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diasorin SpA's current PS Ratio of 3.18 is 13.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Diasorin SpA and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diasorin SpA's current PS Ratio is 3.18, which is 46% below median its own 10-year median of 5.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (WBO:DIAS) is currently considered Modestly Undervalued. The stock's GF Value™ is €90.06, compared to a current price of €69.68 — trading 22.6% below its estimated fair value. The current PS Ratio is 3.18, which is 46% below median its 10-year median of 5.92 and 13.4% above the Medical Diagnostics & Research industry median of 2.81. Diasorin SpA's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Diasorin SpA (WBO:DIAS), the current PS Ratio is 3.18 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diasorin SpA (WBO:DIAS) Overvalued in 2026?
Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued.
The current stock price of €69.68 is trading 22.6% below its estimated GF Value™ of €90.06.
GuruFocus considers Diasorin SpA to be Modestly Undervalued.
Key valuation signals for WBO:DIAS:
PS Ratio: 3.18 (46% below median its 10-year median of 5.92)
GF Value™: €90.06 vs. price of €69.68 (22.6% below fair value)
Industry Position: 13.4% above the Medical Diagnostics & Research median (#110 of 200)
No single metric tells the full story. See the WBO:DIAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
74GF Score
Get the complete analysis for WBO:DIAS
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:DIAS has been successfully added to your 
